Could a single pill prevent HIV and STIs? new study tests doxycycline doses

NCT ID NCT05853120

Completed Knowledge-focused Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested how different doses of the antibiotic doxycycline reach tissues in the body. The goal is to combine it with HIV drugs into a single pill that could be taken just before sex to protect against both HIV and other sexually transmitted infections. 45 healthy adults took doxycycline at 100 or 200 mg doses, and researchers measured drug levels in rectal and vaginal tissues.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: doxycycline
What this could lead to: If successful, this could help create a single-dose pill that protects against both HIV and other sexually transmitted infections.
What could go wrong: This is a small, early-stage study focused on drug levels in tissues, not on actual infection prevention. The results may not lead to an effective prevention strategy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEXUALLY TRANSMITTED DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sexually transmitted disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEXUALLY TRANSMITTED DISEASES

Contacts and locations

Locations

Hope Clinic

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.